Serum CXCL9 levels were significantly higher in NPC patients with higher tumor stages, nodal stages, and overall stages (P<0.001, P = 0.001, and P<0.001, respectively). This evidence concerns the gene CXCL9 and nasopharyngeal carcinoma.